PIRFETAB 200MG TABLET

Manufacturer : GER-GERMAN REMEDIES LIMTED
Composition : PIRFENIDONE-200MG
Dose Form : TABLET
Description : PIRFETAB 200 MG TAB
Route Of Administration : ORAL
Pack : 10
In stock
SKU
PIR0074
₹210.00
Manufacturer : GER-GERMAN REMEDIES LIMTED
Composition : PIRFENIDONE-200MG
Dose Form : TABLET
Description : PIRFETAB 200 MG TAB
Route Of Administration : ORAL
Pack : 10

Drug Ingredient Information

PIRFENIDONE-200MG

PIRFENIDONE

Information for patients
Drug Information Pirfenidone is indicated for the treatment of Idiopathic Pulmonary fibrosis (IPF).
Drug Alert
Alert no data available
Before Consuming the Medicine
Avoid Drug Hypersensitivity to the active substance or to any of the excipients, Concomitant use of fluvoxamine ( see Drug Interactions under WARNINGS AND PRECAUTIONS ) Severe hepatic impairment or end stage liver disease ( see WARNINGS AND PRECAUTIONS and Recommendations for Dose Adjustment ) Severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis
Drug Special Care Gastrointestinal events: In patients who experience intolerance to therapy due to gastrointestinal side effects, patients should be reminded to take the medicinal product with food. If symptoms persist pirfenidone may be reduced to 1-2 tablets given 2-3 times/day with food with re-escalation to the recommended daily dose as tolerated. If symptoms continue, patients may be instructed to interrupt treatment for 1 to 2 weeks to allow symptoms to resolve. Photosensitivity reaction or rash: Patients who experience a mild to moderate photosensitivity reaction or rash should be reminded of the instruction to use a sunblock daily and to avoid sun exposure ( see WARNINGS AND PRECAUTIONS ). The dose of pirfenidone may be reduced to 3 tablets/day (1 tablet three times a day). If the rash persists after 7 days, pirfenidone should be discontinued for 15 days, with re-escalation to the recommended daily dose in the same manner as the dose escalation period. Patients who experience severe photosensitivity reaction or rash should be instructed to interrupt the dose and to seek medical advice. Once the rash has resolved, pirfenidone may be re-introduced and re-escalated up to the recommended daily dose at the discretion of the physician. ( see WARNINGS AND PRECAUTIONS ). Hepatic function: In the event of significant elevation of alanine and /or aspartate aminotransferases (ALT/AST) with or without bilirubin elevation, the dose of pirfenidone should be adjusted or treatment discontinued according to the guidelines listed under (see WARNINGS AND PRECAUTIONS ). Special populations Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment (i.e. Child-Pugh Class A and B). However, since plasma levels of pirfenidone may be increased in some individuals with mild to moderate hepatic impairment, caution should be used with pirfenidone treatment in this population. Patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor ( see WARNINGS AND PRECAUTIONS ). Pirfenidone has not been studied in patients with severe hepatic impairment or end stage liver disease, and it should not be used in patients with these conditions (see WARNINGS AND PRECAUTIONS ). It is recommended to monitor liver function during treatment, and dose adjustments may be necessary in the event of elevations (see WARNINGS AND PRECAUTIONS and Recommendations for Dose Adjustment ). Renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. pirfenidone therapy should not be used in patients with severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis. Paediatric population There is no relevant use of pirfenidone in the paediatric population in the treatment of IPF. Elderly No dose adjustment is necessary in patients 65 years and older.
Drug Drug Interactions no data available
Drug Pregnancy Interaction no data available
Drug Breast feeding Interaction no data available
Drug Machinery Interaction no data available
Drug More Information no data available
How to take the Medicine
Consumption Info no data available
Drug quanitty The initial dose for adults is 200 mg, three times a day (600 mg/day), after a meal. Gradually increase the dose to 600 mg, three times a day (1,800 mg/day), under observation (as per Recommendations for Dosage Adjustment below). Furthermore, appropriately increase or decrease the dose from time to time depending upon the symptoms. Pirfenidone tablet is to be swallowed whole with water and taken with food to reduce the possibility of nausea and dizziness ( see UNDESIRABLE EFFECTS). It is recommended to administer pirfenidone after food/ meals to prevent/reduce side effects. Recommendations for Dose Adjustment Upon initiating treatment, the dose should be titrated to the recommended daily dose of nine tablets per day over a 14-day period as follows: Days 1 to 7: one tablet, three times a day (600 mg/day) Days 8 to 14: two tablets, three times a day (1200 mg/day) Day 15 onward: three tablets, three times a day (1800 mg/day) Patients who miss 14 consecutive days or more of pirfenidone treatment should re-initiate therapy by undergoing the initial 2-week titration regimen up to the recommended daily dose. For treatment interruption of less than 14 consecutive days, the dose can be resumed at the previous recommended daily dose without titration.
Drug Dose no data available
Excess Drug Consumption Dail 1066. OR Contact doctor immediately
Forgot Drug Consumption Contact Your doctor
Stop Drug Consumption Do not stop the drug untill your doctor says you to do so.
Possible Side Effects
General Information no data available
Common Drug Side Effects no data available
Rare Drug Side Effects no data available
Very Rare Drug Side Effects no data available
Drug Side Effects Symptoms no data available
How to Store the Medicine
How to Store the Medicine Store in a cool and dry place.

Substitute Drugs

Write Your Own Review
You're reviewing:PIRFETAB 200MG TABLET
Your Rating